Literature DB >> 12209478

The risk of cardiovascular thrombotic events with selective cyclooxygenase-2 inhibitors.

Vibeke Strand, Marc C Hochberg.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12209478     DOI： 10.1002/art.10560

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN： 0004-3591


× No keyword cloud information.
  9 in total

Review 1.  Perception of risk: the state of COX-2 selective inhibitors.

Authors:  Lee S Simon; Vibeke Strand
Journal:  Curr Rheumatol Rep       Date:  2005-06       Impact factor: 4.592

Review 2.  Anti-inflammatory strategies in hypertension: focus on COX-1 and COX-2.

Authors:  Matthias Hermann; Frank Enseleit; Frank T Ruschitzka
Journal:  Curr Hypertens Rep       Date:  2005-02       Impact factor: 5.369

Review 3.  Do some inhibitors of COX-2 increase the risk of thromboembolic events?: Linking pharmacology with pharmacoepidemiology.

Authors:  David W J Clark; Deborah Layton; Saad A W Shakir
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

Review 4.  Benefit-risk assessment of rofecoxib in the treatment of osteoarthritis.

Authors:  Helmut Schmidt; Barry G Woodcock; Gerd Geisslinger
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

Review 5.  A turbulent decade for NSAIDs: update on current concepts of classification, epidemiology, comparative efficacy, and toxicity.

Authors:  Philip G Conaghan
Journal:  Rheumatol Int       Date:  2011-12-23       Impact factor: 2.631

Review 6.  An update on nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors.

Authors:  Gary W Williams
Journal:  Curr Pain Headache Rep       Date:  2005-12

7.  COX-2: Where are we in 2003? - Be strong and resolute: continue to use COX-2 selective inhibitors at recommended dosages in appropriate patients.

Authors:  Marc C Hochberg
Journal:  Arthritis Res Ther       Date:  2002-12-11       Impact factor: 5.156

8.  Training Self-Administered Acupressure Exercise among Postmenopausal Women with Osteoarthritic Knee Pain: A Feasibility Study and Lessons Learned.

Authors:  Yan Zhang; Chwan-Li Shen; Kim Peck; Jean-Michel Brismée; Susan Doctolero; Di-Fan Lo; Yik Lim; Lixing Lao
Journal:  Evid Based Complement Alternat Med       Date:  2012-10-23       Impact factor: 2.629

9.  COX-2: where are we in 2003?--distinction from NSAIDs becoming blurred.

Authors:  Richard Day
Journal:  Arthritis Res Ther       Date:  2003-02-27       Impact factor: 5.156
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.